Expertise in
20
conditions

Dr. Attaya Suvannasankha

Hematology
Office
980 W Walnut St, 
Indianapolis, IN 
Expertise in
20
conditions
Office
980 W Walnut St, 
Indianapolis, IN 

Overview

Attaya Suvannasankha is a Hematologist practicing medicine in Indianapolis, Indiana.

Dr. Suvannasankha is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 48 peer reviewed articles and participating in 5 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in IN

Hospital Affiliations

Indiana University Health Bloomington Hospital
Indiana University Health
Indiana University Health Ball Memorial Hospital
Indiana University Health North Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Office
980 W Walnut St, Indianapolis, IN 46202
Other Locations
IU Health Simon Cancer Center
1030 W Michigan St, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab
Study Phase: Phase 2
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin Frozen Liquid, Belantamab Mafodotin Lyophilized Powder
Study Phase: Phase 2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drug: STRO-001
Study Phase: Phase 1
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
Enrollment Status: Completed
Publish Date: April 09, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pembrolizumab
Study Phase: Phase 1/Phase 2
Role of Osteocytes in Myeloma Bone Disease
Role of Osteocytes in Myeloma Bone Disease
Enrollment Status: Completed
Publish Date: September 08, 2023
View 4 Less Clinical Trials

48 Total Publications

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 11, 2026
Similar Doctors
Expertise in
6
conditions
Dr. Amy Shapiro
Hematology | Oncology
Expertise in
6
conditions
Dr. Amy Shapiro
Hematology | Oncology

Indiana Hemophilia And Thrombosis Center Inc

8326 Naab Rd, 
Indianapolis, IN 
 (8.3 miles away)
317-871-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amy Shapiro is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Shapiro is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Blood Clots, Hemophilia A, Hemophilia B, and Ligneous Conjunctivitis.

Expertise in
25
conditions
Dr. Nabil Adra
Hematology
Expertise in
25
conditions
Dr. Nabil Adra
Hematology

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (1.3 miles away)
317-944-0920
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nabil Adra is a Hematologist practicing medicine in Indianapolis, Indiana. Dr. Adra is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Testicular Cancer, Teratoma of the Mediastinum, Prostate Cancer, Orchiectomy, and Bone Marrow Transplant.

Expertise in
25
conditions
Dr. Rafat Abonour
Hematology
Expertise in
25
conditions
Dr. Rafat Abonour
Hematology

Office

11645 Illinois St, 
Carmel, IN 
 (11.6 miles away)
317-688-4800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rafat Abonour is a Hematologist practicing medicine in Carmel, Indiana. Dr. Abonour is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Attaya Suvannasankha

How do I make an appointment with Dr. Attaya Suvannasankha?

You can book an appointment with Dr. Attaya Suvannasankha by calling their office at 317-274-0843. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Attaya Suvannasankha a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Attaya Suvannasankha is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Attaya Suvannasankha specialize in?

While Dr. Attaya Suvannasankha is a Hematology, they have specific expertise in Multiple Myeloma, Smoldering Multiple Myeloma, and Monoclonal Gammopathy of Undetermined Significance (MGUS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Attaya Suvannasankha participate in research or clinical trials?

Yes. Dr. Attaya Suvannasankha has published 48 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Attaya Suvannasankha's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Attaya Suvannasankha accept my insurance?

Dr. Attaya Suvannasankha accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-274-0843 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Suvannasankha's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 50 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile